FLT3 and chronic myelogenous leukemia, BCR-ABL1 positive: A previous study has shown that ponatinib, which is the inhibitor of BCR-ABL and fms-like tyrosine kinase 3 (FLT3), is a substrate of P-gp and can reduce the amounts of ABCB1 mRNA in human chronic myelogenous leukemia cell line [108].